# US 9,273,287 B2 · Avian reoviridae and vaccines thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,273,287 B2 - Document ID: US9273287B2 - Status: Granted - Kind: B2 - Application number: 13/000,492 - Filed: 2009-06-26 - Published: 2011-06-23 - Granted: 2016-03-01 - Earliest claimed: 2008-06-26 - Assignees: Biomune Company - Applicants: Kristi Mae Dorsey; John Konx Rosenberger; Sandra Cloud Rosenberger - Inventors: Kristi Mae Dorsey; John Konx Rosenberger; Sandra Cloud Rosenberger - Web page: https://patentgrep.com/patent/US9273287B2 ## CPC - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 39/12: Viral antigens - A61K 39/15: Reoviridae, e.g. calf diarrhea virus - A61P 31/14: for RNA viruses - C07K 14/005: from viruses - G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses - A61K 2039/525: {Virus} - A61K 2039/5252: {inactivated (killed)} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/70: {Multivalent vaccine} - C12N 2720/12221: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2720/12222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2720/12234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2770/12034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - G01N 2333/14: Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses. ## Claims ### Claim 1 A vaccine comprising a peptide encoded by SEQ ID NO: 1 or 2 and an adjuvant selected from aluminum hydroxide, aluminum phosphate, aluminum oxide, an oil-in-water or a water-in-oil emulsion. ### Claim 2 (depends on 1) The vaccine according to claim 1, wherein said oil is a mineral oil, a vegetable oil, vitamin E acetate or a saponin. ### Claim 3 An inactivated avian reoviridae produced by contacting an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297 with formaldehyde, beta-propriolactone or ethylene-imine and inactivating said avian reoviridae. ### Claim 4 (depends on 3) A vaccine comprising the inactivated reoviridae of claim 3 and a pharmaceutically acceptable carrier or diluent. ### Claim 5 (depends on 4) The vaccine of claim 4 further comprising an adjuvant. ### Claim 6 (depends on 5) The vaccine according to claim 5, wherein said adjuvant is aluminum hydroxide, aluminum phosphate, aluminum oxide, an oil-in-water or water-in-oil emulsion. ### Claim 7 (depends on 6) The vaccine according to claim 6, wherein said oil is a mineral oil, a vegetable oil, vitamin E acetate or a saponin. ### Claim 8 (depends on 4) The vaccine of claim 4, wherein the vaccine further comprises one or more vaccine components against a second pathogen infectious to poultry. ### Claim 9 (depends on 4) A kit for poultry vaccination comprising a container comprising a vaccine according to claim 4 and an instruction manual, the instruction manual including information for the administration of at least one dose of said vaccine to poultry for lessening the severity of MAS, RSS or sequelae. ### Claim 10 An attenuated avian reoviridae produced by attenuation of an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297, said attenuation comprising inoculating a primary cell culture with an avian reoviridae deposited at the ATCC under accession number PTA-9301, PTA-9302 or PTA-9297, or passaging said avian reoviridae on said cell culture until a cytopathic effect is obtained, and subsequent freezing, thawing and isolation of said attenuated reoviridae. ### Claim 11 (depends on 10) A vaccine comprising the attenuated reoviridae of claim 10 and a pharmaceutically acceptable carrier or diluent. ### Claim 12 (depends on 11) The vaccine according to claim 11 further comprising an adjuvant. ### Claim 13 (depends on 12) The vaccine according to claim 12, wherein said adjuvant is aluminum hydroxide, aluminum phosphate, aluminum oxide, an oil-in-water or water-in-oil emulsion. ### Claim 14 (depends on 13) The vaccine according to claim 13, wherein said oil is a mineral oil, a vegetable oil, vitamin E acetate or a saponin. ### Claim 15 (depends on 14) The vaccine according to claim 14, wherein said oil is a mineral oil, a vegetable oil, vitamin E acetate or a saponin. ### Claim 16 (depends on 14) The vaccine according to claim 14, wherein said oil is a mineral oil, a vegetable oil, vitamin E acetate or a saponin. ### Claim 17 (depends on 11) The vaccine according to claim 11, wherein the vaccine further comprises one or more vaccine components against a second pathogen infectious to poultry. ### Claim 18 (depends on 11) A kit for poultry vaccination comprising a container comprising a vaccine according to claim 11 and an instruction manual, the instruction manual including information for the administration of at least one dose of said vaccine to poultry for lessening the severity of MAS, RSS or sequelae.